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Abstract A number of health economics works require patient cost estimates as a basic information input. 
However the accuracy of cost estimates remains in general unspecified. We propose to investigate how 
the allocation of indirect costs or overheads can affect the estimation of patient costs in order to allow for 
improvements in the analysis of patient costs estimates. Instead of focusing on the costing method, this 
paper proposes to highlight changes in variance explained observed when a methodology is chosen. We 
compare three overhead allocation methods for a specific Spanish population adjusted using the Clinical 
Risk Groups (CRG), and we obtain different series of full-cost group estimates. As a result, there are 
significant gains in the proportion of the variance explained, depending upon the methodology used. 
Furthermore, we find that the global amount of variation explained by risk adjustment models depends 
mainly on direct costs and is independent of the level of aggregation used in the classification system. 
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Introduction 
An accurate estimation of individual costs is essential in economic evaluation, payment systems 
analysis and in general, in a number of works which can be included into the health economics 
spectrum. Obtaining such individual or patient costs remains a complex challenge and faces 
numerous  obstacles.  The  Bottom  up  microcosting  methodology  refers  to  the  most  detailed 
patient-specific resource consumption measurement and is considered the gold standard in the 
economic evaluation literature. However, its implementation is expensive and time consuming 
[1]. According to Wordsworth et al. [2] Bottom up microcosting is the desirable method for 
labour costs and other cost components that have a great impact on total costs. Tan et al. [3] 
showed how the selection of a different methodology (Top down microcosting or Bottom up 
gross costing) for labour costs and other critical cost components can produce differences in 
patient cost estimates in comparison with the gold standard. Clement et al. [4] investigated to 
what extent the selection of the costing methodology can affect the results of an economic 
evaluation  and  produce  further  wrong  decisions.  Other  problems  accepted  by  the  health 
economics literature in the analysis of individual healthcare costs are the existence of missing 
data [5,6] or the application of inadequate costing methods [7]. 
 
Regardless  of  the  methodological  approach  discussion,  the  allocation  of  overheads  is  a 
problematic question that requires careful attention. Some studies analyse homogeneous patient 
groups using only direct (or marginal) costs [8,9]. Conceptually, direct costs are directly related 
to the activity and in consequence are less susceptible to suffer from arbitrary allocation criteria 
[10].  However,  the  complete  price  of  health  services  requires  the  full  absorption  of  costs. 
Unfortunately, there is a general lack of consensus about the appropriate costing methodology 
[10,11,12], until the point that some authors [13] define the overhead allocation related choices 
as a matter of judgement and common sense.  
  
The motivation for writing this article came up during the development of the research project 
published by Inoriza et al. [14]. The aim of the original project was to classify a specific patient 
population according to morbidity using the Clinical Risk Groups (CRG) model proposed by 
Hughes et al. [15], obtaining also their individual costs. Different costing methodologies should 
be  used  depending  upon  the  purpose.  Considering  the  scope  of  the  project  and  the  data 
available, a retrospective full absorption system was chosen as a suitable method. However, the 
implied overhead absorption and their effect in relation to the patient classification system, 
remained a controversial point for the research team. 
 
In connection to such concern, this paper provides insights for filling that lack of consensus in 
the literature by analyzing the statistical effects caused by the overhead allocation choice. More 
than  focusing  on  the  costing  method,  our  work  proposes  to  highlight  predictive  changes 
observed when an overhead allocation methodology is chosen. Taking a specific population, we 
test different cost allocation methodologies obtaining different series of group averages, from 
which we can measure the proportion of variation of total costs explained by the risk adjustment 
model (R
2). The information system utilized in our estimations is the CRG model, presented in 
Hughes et al. [15]. We use the same concurrent (or retrospective) risk adjustment model in order 
to determine whether our R
2 coefficients belong to a comparable range of values as other papers 
in the literature (above 0.42) using the same information system. Furthermore, the choice of a 
concurrent analysis provides a straightforward tool to observe the statistical effects caused by 
the overhead allocation in an isolated manner. 
 
The  properties  of  the  CRG  information  system  and  its  ability  to  track  different  groups  of 
patients have been widely described [15,16]. However the relation between costing choices and 
the CRG predictive performance has not previously been explored. 
  
The rest of this paper is organised as follows. After this introduction the second section presents 
the data used. Section 3 describes the details on the different cost allocation methodologies. 
Section 4 presents the results and finally, section 5 concludes. 
Data 
Serveis de Salut Integrats del Baix Empordà (SSIBE) is an integrated healthcare management 
organisation. It is responsible for the public provision of health services – including Primary 
Care, Specialised Attention and Acute Hospitalisations – in the county of Baix Empordà in 
Catalunya (Spain). The total population in the Baix Empordà in 2005 was of 90,849 individuals. 
 
In order to control population, morbidity and costs, SSIBE runs an integrated patient database 
with individual information on morbidity (procedures, diagnostic codes, discharge data, ICD9-
CM and other clinical information), services consumption (pharmaceutical and other products) 
and activity records. The original project objective involved classifying individuals into CRG 
categories using the available information on morbidity and obtaining estimates for individual 
costs, taking into account all the available information on health services provided by SSIBE. 
García-Goñi  and  Ibern  [17]  and  García-Goñi  et  al.  [22]  obtained  some  early  results  on 
individual pharmaceutical consumption for years 2002 and 2003 with the same population.  
 
The demographic characteristics and the risk profile of the population are shown in Table I, 
where we can observe how the population is almost equally distributed by gender (50.60% are 
males and 49.40% are females) and 68.32% of the population belong to the category of healthy 
individuals. 
Methods 
Considering patients as the unit level objective in the analysis, we define three different cost 
categories:  Patient  or  direct  costs,  departmental  or  semi-direct  costs  and  indirect  costs  or  
overheads. SSIBE business lines and cost structure are shown in Table II. Only 10.98% of total 
costs belong to the category of direct costs assigned to patients, and 42.24% correspond to the 
cost of main departments. The rest of the total costs corresponds mostly to support units 29.61% 
and indirect costs 17.17%.  
 
The  costing  methodology  we  use  combines  the  Bottom-Up  and  the  Top-Down  approaches 
described in  Mogyorosy and Smith [1]. Thus, we add up direct costs of patients stemming from 
their related clinical records and calculate other costs from the different company departments. 
During  year  2005,  total  expenses  presented  by  the  SSIBE  balance  sheet  accounted  for 
45,868,690.45 € (excluding financial expenses, provisions, stock differences and taxes). In the 
next paragraphs we describe how the methodology deals with the different types of costs. 
 
The first category of costs, direct costs (10.98% of the total expenditures), is obtained by a 
Bottom Up approach as the sum of balance sheet expenses directly related to patients. They 
include  direct  costs  from  blood  transfusions,  prostheses,  intermediate  products,  and 
pharmaceutical consumption. 
 
The second category of costs, departmental costs, suppose the most important proportion of 
costs within the institution (71.85%), and include costs of health services which can be charged 
to patients using average costs and individual patient data on use of services resources (Top-
Down microcosting approach). Examples of the costs recorded in this category are the number 
of hospital stays, laboratory tests or rehabilitation sessions. 
 
Lastly, the third category of costs, indirect costs (supposing 17.17% of total costs) include 
company fixed costs as management, accounting, building amortisation, and other costs not 
related to the activity. Differently to direct and departmental costs, indirect costs cannot be  
assigned directly to patients based on use. Therefore, we need to assign to each patient a fair 
proportion of the general overheads.  
 
The health economics literature has proposed different allocation methods. However, there is no 
common agreement on which of these methodologies is the best to allocate indirect costs. In this 
paper, we utilise and compare three different methods from the list of Bean and Hussey [11]: 
flat rate, output, and actual utilization. A brief description of each methodology is presented as 
follows:  
 
1.  Flat  rate:  under  this  methodology,  overheads  are  shared  equally  among  company 
departments. Since we have at our institution 13 different departments, general overheads 
are simply divided into 13 portions. 
2.  Output: under the output methodology, expenses are assigned proportionally to the different 
departments of the institution depending on the amount of services provided. Thus, general 
overheads are charged to each department according to the ratio: output department / global 
output.  
3.  Actual  utilization:  Proportional  to  the  actual  utilization  of  overhead  costs.  General 
overheads are divided proportionally to the ratio: department overheads / general overheads. 
 
Table III shows the overhead absorption scheme and the monetary value attached to activity 
units under the three methodologies. Using the Flat rate method every department absorbs a 
fixed amount of 605,655.96€, while using the Output and Actual utilization methodologies the 
amount  of  overheads  charged  to  departments  depends  on  the  activity  parameter  or  on 
department overheads respectively. 
 
We calculate estimates for the total cost associated to each individual using three different 
methodologies  for  allocating  indirect  costs,  consequently  we  obtain  three  different  vectors:  
Total Cost Flat Rate, Total Cost Output and Total Cost Actual Utilization. Furthermore, we use the Clinical 
Risk  Groups  (CRG)  classification  system  in  order  to  group  patients  according  to  their 
morbidity,  and  estimate  the  amount  of  variation  explained  using  different  risk  adjustment 
strategies for individual total health costs under the different methodologies. We present and 
compare every allocation cost methodology through the R
2 coefficient, providing information 
on the proportion of variation explained by the concurrent risk adjustment model for individuals 
in year 2005 using morbidity information in the same year. 
Results 
The  CRG  system  allows  classifying  individuals  into  mutually  exclusive  clinical  categories 
attending to their health status. This classification system presents 1,099 CRG categories, which 
can be grouped using four different levels of aggregation: ACRG1 (441 groups), ACRG2 (176 
groups), ACRG3 (46 groups) and core health status rank (9 groups). In this paper we present 
our results on the concurrent risk adjustment model using morbidity information grouped under 
the highest level of aggregation, so that average costs for each category are real costs estimates 
for the population belonging to that risk category during year 2005. 
 
Table  IV  presents  direct  average  costs  (Col.2)  and  total  average  costs  when  an  absorption 
hypothesis  is  chosen  (Col.  3–5).  Looking  at  the  results,  Output  and  Actual  Utilization 
methodologies explain a very similar amount of variation, although the R
2 coefficient is slightly 
higher using the Output absorption method for allocating indirect costs. Total cost averages 
generated by health status through the risk adjustment model are very close, for output and 
actual  utilization  methods,  and  thus,  the  proportion  of  variance  explained  by  the  model  is 
approximately 2 percent higher than the risk adjustment model predicting only individual direct 
costs. In contrast, the Flat Rate methodology differs greatly in terms of variation explained 
because the model tends to charge unhealthy people with large average costs. Hence, comparing 
the flat rate methodology with Output and Actual Utilization methods, total average costs are  
greater  for  status  8  and  9  (worst  health  status).  On  the  other  hand,  using  the  Flat  Rate 
absorption, the variation explained is reduced in respect to the direct cost case. 
 
As expected, using a more detailed scale (ACRG3, ACRG2, ACRG1 or CRG) increases the 
proportion of variation explained by the different methodologies in the concurrent model (when 
current expenditures are predicted through actual CRGs), obtaining an R
2 of about 0.40. Table 
V  shows the relationship between  R
2  and  the  aggregation level. We observe how  the  total 
amount of variance explained by the risk adjustment system depends mainly on the direct cost 
contribution,  without regarding  the level  of  aggregation.  However, adding  the  allocation  of 
indirect  costs  through  the  output  or  actual  utilization  methodologies  makes  the  variation 
explained to increase about 2 percentage points.  
Discussion 
The need for accurate and quality individual cost estimates comes into the overhead allocation, 
in general arbitrary. Moreover, in agreement with Bean and Hussey [11] and Lucey [13], the 
costing literature does not offer a clear solution for the allocation of overheads, even if the 
objective in the analysis is the relation between costing choices and variation explained for a 
risk adjusted population. 
 
A  first  idea,  which  can  be  drawn  from  our  results,  is  that  the  global  amount  of  variation 
explained by the Clinical Risk Groups depends mainly on direct costs. As is shown in table IV, 
the  allocation  of  overheads  just  produces  a  marginal  change  on  the  variation  explained  in 
comparison with using only direct costs. This conclusion can be interpreted in line with the 
results of Tan et al. [3] and Wordsworth et al. [2] in the sense that focusing on critical cost 
components with a large impact on total costs, usually classified as direct costs, the system will 
produce reliable cost estimates regardless of other related specifications. 
  
The previous idea implies a second remarkable consideration. In spite of the variation explained 
depends on direct costs, using a reasonable costing methodology for allocating overheads, being  
the  Output  and  Actual  Utilization  methodologies  the  most  preferred,  the  total  amount  of 
variation explained can be increased. Table V shows how both methods produce a higher R
2 
coefficient for all levels of aggregation; CRG (1,099 groups), ACRG1 (441 groups), ACRG2 
(176 groups), ACRG3 (46 groups) and core health status rank (9 groups). It is important to 
emphasize how the gain in variance obtained is independent of the level of aggregation used in 
the risk adjustment system. Whereas the global amount of variation explained increases using a 
more detailed scale, from health status (R
2 = 0.20) to CRG (R
2 = 0.40), the gain in variance 
caused by the overhead allocation remains constant, about 2 percentage points. 
 
The  results  obtained  for  the  CRG  aggregation  level  (R
2  =  0.40)  are  very  similar  to  those 
obtained by Hughes et al. [15] for the concurrent model (R
2 = 0.42). Although the use of a 
concurrent analysis, without exploring the prospective implications, is a limitation of the study, 
such  method  seems  to  be  useful  in  order  to  isolate  the  statistical  effects  produced  by  the 
overhead allocation. The alternative is the prospective approach, but some statistical distortion 
produced by combining information from different years would be included with certainty. 
 
Other limitations of the study are as follows: According to Carey and Burgess [18] costing 
choices can be affected by many other factors not related to patient costs; the different needs 
that a cost system have to satisfy, the coexistence of a secondary costing system in the same 
company or the presence of financial incentives addressed to obtain certain results [19]. A 
general theoretical framework for accounting choices exists, e.g. Fields et al. [20]. However, it 
is lacking considering the perspective from which our study is proposed. Another limitation 
arises from using an unique risk assessment model, the study of the Society of Actuaries [21] 
evaluated 12 diagnosis and/or pharmacy based models: Adjustment Clinical Groups (ACGs) (2 
versions),  Chronic  Illness  and  Disability  Payment  System  (CDPS),  Clinical  Risk  Groups  
(CRG), Diagnostic Cost Groups (DCGs), Episode Risk Groups (ERGs), Impact Pro, MEDai, 
Medicaid Rx, Pharmacy Risk Groups (PRGs), Rx Groups Risk Smart and Underwriting Model 
Risk  Smart.  To  investigate  whether  a  similar  hypothesis  produces  similar  results  for  other 
important risk assessment models would be interesting for future research works. 
 
The CRG properties have been accurately described by works as Hughes et al. [15] or Neff et al. 
[16].  From  a different perspective  certain  problems,  which  arise from  building  costs  at the 
patient level, have been previously discussed in the costing literature. Our work combines both 
approaches, exploring the CRG sensibility to a specific class of costing choices, those related to 
overheads allocation. 
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Table I. Demographic characteristics of the population 
Demographic characteristics    
     
Female  49.40% 
Male  50.60% 
     
Age (mean)  40.45 
0-14  14.99% 
15-29  19.79% 
30-44  25.28% 
45-64  21.89% 
65-79  11.97% 
80 or older  6.07% 
     
Aggregated clinical risk group categories of patients    
Healthy  68.32% 
History of significant acute disease  9.17% 
Single minor chronic disease  5.72% 
Minor chronic disease in multiple organ system  0.85% 
Single dominant or moderate chronic disease  10.74% 
Disease in chronic multiple organ systems  4.34% 
Dominant chronic disease in three or more organ systems  0.34% 
Dominant and metastatic malignancies  0.33% 
Catastrophic conditions  0.19% 
Note: N=90,849 individuals.    
  
 
Table II. Company cost structure 
   Direct costs  Indirect costs  %   
           
Direct costs          
   Patient costs  5,034,972.65  ---  10.98% 
           
Departmental costs. Main departments          
   Primary Care  6,224,866.43  4,535,879.18  23.46% 
   Inpatient Hospital  3,991,965.29  1,264,058.73  11.46% 
   Outpatient Hospital  2,095,646.09  1,262,709.28  7.32% 
           
Departmental costs. Support departments          
   Emergencies  4,277,816.11  61,174.21  9.46% 
   Surgical Area  3,352,119.21  226,200.19  7.80% 
   Laboratory  1,775,725.10  96,210.47  4.08% 
   Radiology  1,153,040.34  180,853.96  2.91% 
   Haemodialysis  846,107.44  70,060.00  2.00% 
   Rehabilitation  510,443.86  18,529.34  1.15% 
   MA Surgery – Day Hospital  501,056.34  15,328.61  1.13% 
   Hyperbaric Medicine  234,936.46  7,256.01  0.53% 
   Short stay units  143,922.23  4,984.68  0.32% 
          
Departmental costs. Other departments         
   Podology, Sports Medicine  105,286.22  4,014.58  0.24% 
           
Indirect costs          
   General overheads  ---  7,873,527.43  17.17% 
Total costs  30,247,903.77  15,620,786.67  100.00%  
Table III. Department overhead absorption and monetary value attached to activity units  
Departments     Unit     Activity     Flat rate     Output     Actual utilization 
                                     
Main departments                Absorption  Unit value    Absorption  Unit value    Absorption  Unit value 
   Primary Care     Visit     612,609    605,655.96  0.99    4,271,903.80  6.97    4,609,806.90  7.52 
   Inpatient Hospital     Stay     33,224    605,655.96  18.23    231,680.78  6.97    1,284,660.91  38.67 
   Outpatient Hospital     Visit     132,501    605,655.96  4.57    923,968.67  6.97    1,283,289.46  9.69 
                                     
Support departments                                    
   Emergencies     Emergency     52,940    605,655.96  11.44    369,166.28  6.97    62,171.26  1.17 
   Surgical Area    Intervention    4,522    605,655.96  133.94    31,533.24  6.97    229,886.90  50.84 
   Laboratory     Test      126,821    605,655.96  4.78    884,360.35  6.97    97,778.55  0.77 
   Radiology     Image     73,506    605,655.96  8.24    512,579.09  6.97    183,801.60  2.50 
   Haemodialysis     Session     6,851    605,655.96  88.40    47,774.05  6.97    71,201.87  10.39 
   Rehabilitation     Session     73,181    605,655.96  8.28    510,312.76  6.97    18,831.34  0.26 
   MA Surgery – Day Hospital     Session     6,769    605,655.96  89.47    47,202.24  6.97    15,578.44  2.30 
   Hyperbaric Medicine     Session     621    605,655.96  975.29    4,330.42  6.97    7,374.27  11.87 
   Short stay units     Stay     777    605,655.96  779.48    5,418.25  6.97    5,065.92  6.52 
                                     
Other departments                                    
   Podology, Sports Medicine     Visit     4,775    605,655.96  126.84    33,297.49  6.97    4,080.01  0.85 
Total          1,129,097    7,873,527.43  ---    7,873,527.43  ---    7,873,527.43  ---  
Table IV. Average costs by core health status 
      Direct cost    Total cost * 
                  
Core Health Status          Flat rate  Output  Act. Utilization 
1. Healthy     103.23    122.95  135.54  134.12 
2. History of significant acute disease     618.81    755.84  753.63  756.88 
3. Single minor chronic disease     345.37    424.65  447.40  438.81 
4. Minor chronic disease in multiple organ system     530.85    646.56  684.01  671.53 
5. Single dominant or moderate chronic disease     552.04    651.47  690.87  686.75 
6. Disease in chronic multiple organ systems     1,187.33    1,418.75  1,423.08  1,438.81 
7. Dominant chronic disease in three or more organ systems  2,724.29    3,156.97  3,113.31  3,245.82 
8. Dominant and metastatic malignancies     3,111.54    3,694.13  3,462.10  3,563.67 
9. Catastrophic conditions     10,111.84    12,967.94  10,565.02  10,683.51 
                  
Variation explained                 
R
2     0.1889    0.1887  0.2046  0.2029 
* Total cost include direct cost and overhead absorption                 
  
 
Table V. Variation explained by aggregation level for the CRG concurrent model 
   R
2  
   Direct cost  Flat Rate  Output  Act. Utilization 
              
Aggregation Level             
Health status  0.1889  0.1877  0.2046  0.2029 
ACRG3  0.2684  0.2796  0.2896  0.2905 
ACRG2  0.3262  0.3526  0.3469  0.3477 
ACRG1  0.3458  0.3692  0.3668  0.3686 
CRG  0.3784  0.3977  0.3989  0.4021 
 